AKT1 and breast neoplasm: Given the importance of the PI3K/Akt/mTOR pathway in breast tumor progression, further research is required to understand the impact of such drugs on the TME, which may reduce cytotoxic effects and enhance the anti-tumor function of other standard treatment regimens.